Pathologic confirmation of lung adenocarcinoma with measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded on CT); Patients must have previously untreated locally advanced or metastatic NSCLC; Patients must have lung cancer with a documented EGFR activating mutation (exon 19 deletion, L858R).

NCT01665417_inc_T1
Condition
lung adenocarcinoma
NCT01665417_inc_T2
Procedure
Pathologic
NCT01665417_inc_T3
Value
confirmation
NCT01665417_inc_T4
Qualifier
with measurable disease
NCT01665417_inc_T5
Multiplier
at least one
NCT01665417_inc_T6
Condition
lesion
NCT01665417_inc_T7
Qualifier
can be accurately measured in at least one dimension
NCT01665417_inc_T8
Qualifier
untreated
NCT01665417_inc_T9
Qualifier
locally advanced
NCT01665417_inc_T10
Qualifier
metastatic
NCT01665417_inc_T11
Condition
NSCLC
NCT01665417_inc_T12
Scope
locally advanced or metastatic
NCT01665417_inc_T13
Condition
lung cancer
NCT01665417_inc_T14
Qualifier
with EGFR activating mutation
NCT01665417_inc_T15
Condition
exon 19 deletion
NCT01665417_inc_T16
Condition
L858R
NCT01665417_inc_T17
Scope
exon 19 deletion, L858R
NCT01665417_inc_T18
Scope
lung adenocarcinoma with measurable disease